ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Passage Bio Inc

Passage Bio Inc (PASG)

0.65
0.0019
(0.29%)
Closed December 24 4:00PM
0.65
0.00
( 0.00% )
Pre Market: 4:00AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.65
Bid
0.65
Ask
0.85
Volume
-
0.00 Day's Range 0.00
0.451 52 Week Range 1.79
Market Cap
Previous Close
0.65
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
618,641
Shares Outstanding
61,767,286
Dividend Yield
-
PE Ratio
-0.39
Earnings Per Share (EPS)
-1.65
Revenue
-
Net Profit
-102.06M

About Passage Bio Inc

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Passage Bio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PASG. The last closing price for Passage Bio was $0.65. Over the last year, Passage Bio shares have traded in a share price range of $ 0.451 to $ 1.79.

Passage Bio currently has 61,767,286 shares outstanding. The market capitalization of Passage Bio is $40.15 million. Passage Bio has a price to earnings ratio (PE ratio) of -0.39.

PASG Latest News

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from...

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.01892.99477103470.63110.720.69218180.65876555CS
4-0.13-16.66666666670.781.330.613817430.99234735CS
12000.651.330.4516186410.86706856CS
26-0.28-30.10752688170.931.330.4514283180.84046119CS
52-0.2867-30.60745169210.93671.790.4513540951.00567942CS
156-6.06-90.31296572286.716.710.4513302291.51311661CS
260-21.62-97.081275258222.2738.230.4513209757.00291125CS

PASG - Frequently Asked Questions (FAQ)

What is the current Passage Bio share price?
The current share price of Passage Bio is $ 0.65
How many Passage Bio shares are in issue?
Passage Bio has 61,767,286 shares in issue
What is the market cap of Passage Bio?
The market capitalisation of Passage Bio is USD 40.15M
What is the 1 year trading range for Passage Bio share price?
Passage Bio has traded in the range of $ 0.451 to $ 1.79 during the past year
What is the PE ratio of Passage Bio?
The price to earnings ratio of Passage Bio is -0.39
What is the reporting currency for Passage Bio?
Passage Bio reports financial results in USD
What is the latest annual profit for Passage Bio?
The latest annual profit of Passage Bio is USD -102.06M
What is the registered address of Passage Bio?
The registered address for Passage Bio is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Passage Bio website address?
The website address for Passage Bio is www.passagebio.com/home/default.aspx
Which industry sector does Passage Bio operate in?
Passage Bio operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MGIHMillennium Group International Holdings Ltd
$ 3.74
(144.44%)
5.29M
ADDColor Star Technology Company Ltd
$ 4.91
(127.31%)
2.68M
TIRXTian Ruixiang Holdings Ltd
$ 3.09
(52.97%)
252.55k
WAFUWah Fu Education Group Ltd
$ 2.52
(44.83%)
3.37M
LICNLichen China Limited
$ 0.2814
(33.94%)
11.84M
NEUPNeuphoria Therapeutics Inc
 4.10
(-38.16%)
27.47k
HOURHour Loop Inc
$ 2.95
(-32.95%)
177.99k
CREVCarbon Revolution Public Ltd
$ 6.59
(-28.06%)
27.75k
BAOSBaosheng Media Group Holdings Ltd
$ 5.26
(-25.92%)
47.46k
AVGRAvinger Inc
$ 1.09
(-24.83%)
292.83k
LICNLichen China Limited
$ 0.2814
(33.94%)
11.84M
MGIHMillennium Group International Holdings Ltd
$ 3.74
(144.44%)
5.29M
WAFUWah Fu Education Group Ltd
$ 2.52
(44.83%)
3.37M
LITMSnow Lake Resources Ltd
$ 0.6656
(13.80%)
3.33M
LAESSEALSQ Corporation
$ 5.535
(1.19%)
2.92M

PASG Discussion

View Posts
PonkenPlonken PonkenPlonken 2 weeks ago
make or break
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 3 weeks ago
Wedbush pump losing steam
the dilemma is the readouts are right around the corner
๐Ÿ‘๏ธ0
Stumblebum Stumblebum 4 weeks ago
Next week should be interestingโ€ฆ.will Pasg hold its gains or tankโ€ฆwas it a pump and dump dayโ€ฆ..15 million share volume today โ€ฆ..massive increase โ€ฆ..hmmmmm
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 4 weeks ago
EVERYTHING the analyst said today was well known.
Direct CNS delivery... AAV gene therapy pioneer thinks AAV gene therapy will work in FTD too.... First one of its kind in FTD.... Then in recent months we got about a million validations of that ---------- No one bit this? They didnt believe him? Because he left again for head of gene therapy at PENNs and then went on to found 2 new companies instead of linger around at PASG at 60 something years?
No one believed he gave the steering wheel to Mr Chou because Wilson thought Chou could finish the job?
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 4 weeks ago
Analyst says most basic stuff and they go crazy?
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 4 weeks ago
will it keep going?
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 5 months ago
big pop coming. Science hated for no reason. Founder is gene therapy authority. AAV tech works.
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
PASG 10Q due AUGUST5
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 5 months ago
See the first rally on this after the big bar on the first data release. They saw something and took a seat. A lot of shares were bought. Thats because the platform works and will -- veeery surprisingly -- produce great data.
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 5 months ago
this is not a daytrade. I am invested here, waiting for the crowd/data.
I think a deal is coming on data release.... its a neglected approach. Founder is a genius and gene therapy authority, popularized AAVs. All the recent bio winners use them.
Happy trading
๐Ÿ‘๏ธ0
Awl416 Awl416 5 months ago
Ahem..
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 5 months ago
Going to explode on the next readout

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations


๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
There are close to 1,000 listed med tech companies
Only so many can garner serious institutional interest
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 6 months ago
I wonder... when will people realize that the AAV stuff is great... CADL, SLDB, PASG

The founder certainly thinks so... and he is the authority on the topic:
"Dr. James M. Wilson serves as the Director of the Gene Therapy Program (GTP) at Penn's Perelman School of Medicine."

"The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. More recently Dr. Wilsonโ€™s laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy.The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. More recently Dr. Wilsonโ€™s laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy."
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
PASG under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
PASG under $2
๐Ÿ‘๏ธ0
Sirpeter Sirpeter 9 months ago
Running... boom!!!
๐Ÿ‘๏ธ0
Monksdream Monksdream 9 months ago
PASG under $2
๐Ÿ‘๏ธ0
glenn1919 glenn1919 9 months ago
PASG..........................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Monksdream Monksdream 10 months ago
PASG new 52 week high
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 10 months ago
PASG setting up nicely. Another beautiful call by the only true chartist around
๐Ÿ‘๏ธ0
Sirpeter Sirpeter 10 months ago
Yup yup yup...
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 10 months ago
PASG...NEXT CRDL
๐Ÿ‘๏ธ0
glenn1919 glenn1919 10 months ago
PASG..............................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
glenn1919 glenn1919 10 months ago
PASG..............................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Monksdream Monksdream 10 months ago
PASG under $2
๐Ÿ‘๏ธ0
turning stone turning stone 11 months ago
As a new investor in PASG, I am looking forward to another high roller in the next number of years. I bought ARNA years ago at 1.90 and rode it out to $99/share when they were bought out by Phizer Pharm. I would like to have my 5 grandkids share the spoils on this one. With a multi-pipe line, a couple should make it to the end of the line with FDA approval. At the number of shares I purchased multiple times I can afford to run for the hills if a sudden disaster should hit this one. This company is 21 miles from my home and I will stop by shortly and have a sit down with their home-based PR. person. Good luck to all. You may also want to look at BLRX {BIO-Line Inc }










๐Ÿ‘๏ธ0
Walter4 Walter4 1 year ago
Data readout should be incoming shortly
👍️ 1
Monksdream Monksdream 1 year ago
PASG new 52 week low
๐Ÿ‘๏ธ0
catinhat catinhat 3 years ago
So...anybody out there? Thoughts on upcoming abstract, etc?

Recent long.
๐Ÿ‘๏ธ0
dealerschool2006 dealerschool2006 4 years ago
PASG down from panic selling due to the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $22.00 per share.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock